PURPOSE: To determine the expression and functions of protein tyrosine phosphatase nonreceptor type 12 (PTPN12) in renal cell carcinoma (RCC). METHODS: All RCC tissue and corresponding normal kidney tissue from 116 RCC patients undergoing radical nephrectomy were examined. PTPN12 expression was detected by immunohistochemistry, and PTPN12 mRNA expression by real-time polymerase chain reaction (RT-PCR). PTPN12 expression was increased by stable transfection with a pcDEF3 vector containing full-length cDNA of PTPN12 and was decreased by RNAi in 4 RCC cell lines. Proliferative analysis of RCC cells was done using a WST-1 assay and animal xenograft study. RESULTS: PTPN12 expression in RCC tissue was significantly decreased compared with normal kidney tissue, and was overexpressed in larger tumors, metastasis, and high pathological grades. CONCLUSIONS: PTPN12 expression decreases in human RCC, it is involved in progression and metastasis, and is an independent prognostic factor in RCC. Restoring PTPN12 activity could be a new therapeutic approach in advanced RCC.
PURPOSE: To determine the expression and functions of protein tyrosine phosphatase nonreceptor type 12 (PTPN12) in renal cell carcinoma (RCC). METHODS: All RCC tissue and corresponding normal kidney tissue from 116 RCCpatients undergoing radical nephrectomy were examined. PTPN12 expression was detected by immunohistochemistry, and PTPN12 mRNA expression by real-time polymerase chain reaction (RT-PCR). PTPN12 expression was increased by stable transfection with a pcDEF3 vector containing full-length cDNA of PTPN12 and was decreased by RNAi in 4 RCC cell lines. Proliferative analysis of RCC cells was done using a WST-1 assay and animal xenograft study. RESULTS:PTPN12 expression in RCC tissue was significantly decreased compared with normal kidney tissue, and was overexpressed in larger tumors, metastasis, and high pathological grades. CONCLUSIONS:PTPN12 expression decreases in humanRCC, it is involved in progression and metastasis, and is an independent prognostic factor in RCC. Restoring PTPN12 activity could be a new therapeutic approach in advanced RCC.
Authors: Sören A Weidemann; Charlotte Sauer; Andreas M Luebke; Christina Möller-Koop; Stefan Steurer; Claudia Hube-Magg; Franziska Büscheck; Doris Höflmayer; Maria Christina Tsourlakis; Till S Clauditz; Ronald Simon; Guido Sauter; Cosima Göbel; Patrick Lebok; David Dum; Christoph Fraune; Simon Kind; Sarah Minner; Jakob Izbicki; Thorsten Schlomm; Hartwig Huland; Hans Heinzer; Eike Burandt; Alexander Haese; Markus Graefen; Asmus Heumann Journal: BMC Cancer Date: 2019-10-12 Impact factor: 4.430